In addition, HCC with mutant p53 showed poorer clinical responses to TKIs than wild-type p53, which also suggest that strategies to restore p53 levels or improve downstream of p53 pathway might promote the therapeutic sensitivity of cancer cells to TKIs. This evidence concerns the gene TP53 and cancer.